nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—RET—epilepsy syndrome	0.126	0.385	CbGaD
Sorafenib—RALBP1—Carbamazepine—epilepsy syndrome	0.069	0.176	CbGbCtD
Sorafenib—KDR—epilepsy syndrome	0.0661	0.202	CbGaD
Sorafenib—ABCC2—epilepsy syndrome	0.0391	0.119	CbGaD
Sorafenib—ABCG2—epilepsy syndrome	0.0346	0.106	CbGaD
Sorafenib—CYP2C19—epilepsy syndrome	0.0272	0.083	CbGaD
Sorafenib—CYP2D6—epilepsy syndrome	0.0201	0.0615	CbGaD
Sorafenib—ABCB1—epilepsy syndrome	0.0144	0.0439	CbGaD
Sorafenib—ABCC2—Levetiracetam—epilepsy syndrome	0.0126	0.0321	CbGbCtD
Sorafenib—UGT1A9—Propofol—epilepsy syndrome	0.0122	0.031	CbGbCtD
Sorafenib—UGT1A1—Propofol—epilepsy syndrome	0.00996	0.0254	CbGbCtD
Sorafenib—UGT1A9—Valproic Acid—epilepsy syndrome	0.0087	0.0222	CbGbCtD
Sorafenib—ABCC2—Carbamazepine—epilepsy syndrome	0.00724	0.0185	CbGbCtD
Sorafenib—ABCC2—Phenytoin—epilepsy syndrome	0.0065	0.0166	CbGbCtD
Sorafenib—CYP2B6—Fosphenytoin—epilepsy syndrome	0.00641	0.0163	CbGbCtD
Sorafenib—ABCC2—Phenobarbital—epilepsy syndrome	0.00579	0.0148	CbGbCtD
Sorafenib—CYP3A5—Oxcarbazepine—epilepsy syndrome	0.00578	0.0147	CbGbCtD
Sorafenib—CYP2B6—Clobazam—epilepsy syndrome	0.00556	0.0142	CbGbCtD
Sorafenib—CYP2C8—Trimethadione—epilepsy syndrome	0.00516	0.0132	CbGbCtD
Sorafenib—CYP2C8—Fosphenytoin—epilepsy syndrome	0.00486	0.0124	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Carbamazepine—epilepsy syndrome	0.00484	0.0123	CbGbCtD
Sorafenib—CYP3A7—Carbamazepine—epilepsy syndrome	0.00484	0.0123	CbGbCtD
Sorafenib—CYP2C19—Oxcarbazepine—epilepsy syndrome	0.00466	0.0119	CbGbCtD
Sorafenib—CYP2B6—Carbamazepine—epilepsy syndrome	0.00461	0.0117	CbGbCtD
Sorafenib—CYP3A7—Phenytoin—epilepsy syndrome	0.00434	0.0111	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Phenytoin—epilepsy syndrome	0.00434	0.0111	CbGbCtD
Sorafenib—CYP2C19—Trimethadione—epilepsy syndrome	0.00433	0.011	CbGbCtD
Sorafenib—CYP2C19—Felbamate—epilepsy syndrome	0.00433	0.011	CbGbCtD
Sorafenib—CYP2B6—Primidone—epilepsy syndrome	0.0043	0.011	CbGbCtD
Sorafenib—CYP2B6—Phenytoin—epilepsy syndrome	0.00413	0.0105	CbGbCtD
Sorafenib—ABCB1—Levetiracetam—epilepsy syndrome	0.00411	0.0105	CbGbCtD
Sorafenib—CYP2C19—Fosphenytoin—epilepsy syndrome	0.00407	0.0104	CbGbCtD
Sorafenib—CYP3A7—Phenobarbital—epilepsy syndrome	0.00387	0.00985	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Phenobarbital—epilepsy syndrome	0.00387	0.00985	CbGbCtD
Sorafenib—CYP2B6—Propofol—epilepsy syndrome	0.00385	0.00982	CbGbCtD
Sorafenib—CYP3A7—Midazolam—epilepsy syndrome	0.00381	0.00971	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Midazolam—epilepsy syndrome	0.00381	0.00971	CbGbCtD
Sorafenib—CYP2B6—Phenobarbital—epilepsy syndrome	0.00368	0.00938	CbGbCtD
Sorafenib—CYP3A7—Diazepam—epilepsy syndrome	0.00367	0.00934	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Diazepam—epilepsy syndrome	0.00367	0.00934	CbGbCtD
Sorafenib—CYP2B6—Midazolam—epilepsy syndrome	0.00363	0.00925	CbGbCtD
Sorafenib—CYP3A5—Carbamazepine—epilepsy syndrome	0.00363	0.00924	CbGbCtD
Sorafenib—CYP2C9—Trimethadione—epilepsy syndrome	0.0036	0.00918	CbGbCtD
Sorafenib—CYP2C19—Clobazam—epilepsy syndrome	0.00353	0.009	CbGbCtD
Sorafenib—CYP2B6—Diazepam—epilepsy syndrome	0.00349	0.00889	CbGbCtD
Sorafenib—CYP2C8—Carbamazepine—epilepsy syndrome	0.00349	0.00889	CbGbCtD
Sorafenib—CYP2C9—Fosphenytoin—epilepsy syndrome	0.00339	0.00863	CbGbCtD
Sorafenib—CYP2C8—Primidone—epilepsy syndrome	0.00326	0.0083	CbGbCtD
Sorafenib—CYP3A5—Phenytoin—epilepsy syndrome	0.00325	0.00829	CbGbCtD
Sorafenib—CYP2C8—Phenytoin—epilepsy syndrome	0.00313	0.00797	CbGbCtD
Sorafenib—CYP2C19—Carbamazepine—epilepsy syndrome	0.00293	0.00746	CbGbCtD
Sorafenib—CYP2C8—Propofol—epilepsy syndrome	0.00292	0.00743	CbGbCtD
Sorafenib—CYP3A5—Phenobarbital—epilepsy syndrome	0.0029	0.00739	CbGbCtD
Sorafenib—CYP3A5—Midazolam—epilepsy syndrome	0.00286	0.00729	CbGbCtD
Sorafenib—ABCB1—Clobazam—epilepsy syndrome	0.00285	0.00726	CbGbCtD
Sorafenib—CYP2C8—Phenobarbital—epilepsy syndrome	0.00279	0.00711	CbGbCtD
Sorafenib—CYP2B6—Valproic Acid—epilepsy syndrome	0.00275	0.00701	CbGbCtD
Sorafenib—CYP3A5—Diazepam—epilepsy syndrome	0.00275	0.00701	CbGbCtD
Sorafenib—ABCB1—Lamotrigine—epilepsy syndrome	0.00274	0.00699	CbGbCtD
Sorafenib—CYP2C19—Primidone—epilepsy syndrome	0.00273	0.00696	CbGbCtD
Sorafenib—CYP1A2—Carbamazepine—epilepsy syndrome	0.0027	0.00688	CbGbCtD
Sorafenib—CYP2C8—Diazepam—epilepsy syndrome	0.00264	0.00674	CbGbCtD
Sorafenib—CYP2C19—Phenytoin—epilepsy syndrome	0.00262	0.00669	CbGbCtD
Sorafenib—CYP1A2—Primidone—epilepsy syndrome	0.00252	0.00642	CbGbCtD
Sorafenib—CYP2C19—Propofol—epilepsy syndrome	0.00245	0.00624	CbGbCtD
Sorafenib—CYP2C9—Carbamazepine—epilepsy syndrome	0.00243	0.0062	CbGbCtD
Sorafenib—ABCB1—Carbamazepine—epilepsy syndrome	0.00236	0.00602	CbGbCtD
Sorafenib—CYP2C19—Phenobarbital—epilepsy syndrome	0.00234	0.00596	CbGbCtD
Sorafenib—CYP2C9—Primidone—epilepsy syndrome	0.00227	0.00579	CbGbCtD
Sorafenib—CYP1A2—Propofol—epilepsy syndrome	0.00226	0.00576	CbGbCtD
Sorafenib—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.00225	0.00574	CbGbCtD
Sorafenib—CYP2C19—Diazepam—epilepsy syndrome	0.00222	0.00565	CbGbCtD
Sorafenib—CYP2C9—Phenytoin—epilepsy syndrome	0.00218	0.00556	CbGbCtD
Sorafenib—CYP3A5—Valproic Acid—epilepsy syndrome	0.00217	0.00552	CbGbCtD
Sorafenib—CYP2C19—Zonisamide—epilepsy syndrome	0.00216	0.00552	CbGbCtD
Sorafenib—CYP1A2—Phenobarbital—epilepsy syndrome	0.00216	0.0055	CbGbCtD
Sorafenib—ABCB1—Phenytoin—epilepsy syndrome	0.00212	0.0054	CbGbCtD
Sorafenib—CYP3A4—Felbamate—epilepsy syndrome	0.00209	0.00534	CbGbCtD
Sorafenib—CYP3A4—Trimethadione—epilepsy syndrome	0.00209	0.00534	CbGbCtD
Sorafenib—CYP2C8—Valproic Acid—epilepsy syndrome	0.00208	0.00531	CbGbCtD
Sorafenib—CYP1A2—Diazepam—epilepsy syndrome	0.00205	0.00521	CbGbCtD
Sorafenib—CYP2C9—Propofol—epilepsy syndrome	0.00204	0.00519	CbGbCtD
Sorafenib—CYP3A4—Fosphenytoin—epilepsy syndrome	0.00197	0.00502	CbGbCtD
Sorafenib—CYP2C9—Phenobarbital—epilepsy syndrome	0.00195	0.00496	CbGbCtD
Sorafenib—ABCB1—Phenobarbital—epilepsy syndrome	0.00189	0.00481	CbGbCtD
Sorafenib—ABCB1—Midazolam—epilepsy syndrome	0.00186	0.00474	CbGbCtD
Sorafenib—CYP2D6—Propofol—epilepsy syndrome	0.00186	0.00474	CbGbCtD
Sorafenib—CYP2C9—Diazepam—epilepsy syndrome	0.00184	0.0047	CbGbCtD
Sorafenib—ABCB1—Diazepam—epilepsy syndrome	0.00179	0.00456	CbGbCtD
Sorafenib—CYP3A4—Clonazepam—epilepsy syndrome	0.00178	0.00454	CbGbCtD
Sorafenib—CYP2C19—Valproic Acid—epilepsy syndrome	0.00175	0.00445	CbGbCtD
Sorafenib—CYP3A4—Clobazam—epilepsy syndrome	0.00171	0.00435	CbGbCtD
Sorafenib—CYP1A2—Valproic Acid—epilepsy syndrome	0.00161	0.00411	CbGbCtD
Sorafenib—CYP2C19—Topiramate—epilepsy syndrome	0.00158	0.00402	CbGbCtD
Sorafenib—CYP2C9—Valproic Acid—epilepsy syndrome	0.00145	0.0037	CbGbCtD
Sorafenib—CYP3A4—Rufinamide—epilepsy syndrome	0.00145	0.0037	CbGbCtD
Sorafenib—CYP3A4—Carbamazepine—epilepsy syndrome	0.00141	0.0036	CbGbCtD
Sorafenib—CYP3A4—Primidone—epilepsy syndrome	0.00132	0.00337	CbGbCtD
Sorafenib—CYP3A4—Phenytoin—epilepsy syndrome	0.00127	0.00323	CbGbCtD
Sorafenib—CYP3A4—Propofol—epilepsy syndrome	0.00118	0.00302	CbGbCtD
Sorafenib—CYP3A4—Acetazolamide—epilepsy syndrome	0.00113	0.00288	CbGbCtD
Sorafenib—CYP3A4—Phenobarbital—epilepsy syndrome	0.00113	0.00288	CbGbCtD
Sorafenib—CYP3A4—Midazolam—epilepsy syndrome	0.00112	0.00284	CbGbCtD
Sorafenib—CYP3A4—Diazepam—epilepsy syndrome	0.00107	0.00273	CbGbCtD
Sorafenib—CYP3A4—Zonisamide—epilepsy syndrome	0.00105	0.00267	CbGbCtD
Sorafenib—Regorafenib—TEK—epilepsy syndrome	0.00097	0.285	CrCbGaD
Sorafenib—Regorafenib—RET—epilepsy syndrome	0.000902	0.265	CrCbGaD
Sorafenib—CYP3A4—Valproic Acid—epilepsy syndrome	0.000845	0.00215	CbGbCtD
Sorafenib—CYP3A4—Topiramate—epilepsy syndrome	0.000763	0.00194	CbGbCtD
Sorafenib—CDKL2—nervous system—epilepsy syndrome	0.000552	0.0105	CbGeAlD
Sorafenib—CDKL2—central nervous system—epilepsy syndrome	0.000531	0.0101	CbGeAlD
Sorafenib—MAPK15—head—epilepsy syndrome	0.000524	0.01	CbGeAlD
Sorafenib—MAPK11—telencephalon—epilepsy syndrome	0.000499	0.00953	CbGeAlD
Sorafenib—MAPK15—nervous system—epilepsy syndrome	0.000497	0.00949	CbGeAlD
Sorafenib—RAF1—hindbrain—epilepsy syndrome	0.000487	0.00931	CbGeAlD
Sorafenib—MAPK15—central nervous system—epilepsy syndrome	0.000478	0.00914	CbGeAlD
Sorafenib—Regorafenib—KDR—epilepsy syndrome	0.000474	0.139	CrCbGaD
Sorafenib—CDKL3—brain—epilepsy syndrome	0.000461	0.00881	CbGeAlD
Sorafenib—CDKL2—brain—epilepsy syndrome	0.000422	0.00806	CbGeAlD
Sorafenib—MAP2K5—hindbrain—epilepsy syndrome	0.000414	0.00792	CbGeAlD
Sorafenib—HTR2C—ganglion—epilepsy syndrome	0.000399	0.00762	CbGeAlD
Sorafenib—MAPK15—brain—epilepsy syndrome	0.00038	0.00725	CbGeAlD
Sorafenib—KIT—hindbrain—epilepsy syndrome	0.000367	0.00701	CbGeAlD
Sorafenib—FGFR1—telencephalon—epilepsy syndrome	0.000316	0.00604	CbGeAlD
Sorafenib—MAPK11—head—epilepsy syndrome	0.000311	0.00594	CbGeAlD
Sorafenib—CDK7—head—epilepsy syndrome	0.000306	0.00584	CbGeAlD
Sorafenib—AURKC—head—epilepsy syndrome	0.000301	0.00575	CbGeAlD
Sorafenib—MAP3K7—telencephalon—epilepsy syndrome	0.000299	0.00572	CbGeAlD
Sorafenib—MAPK11—nervous system—epilepsy syndrome	0.000295	0.00563	CbGeAlD
Sorafenib—MKNK2—telencephalon—epilepsy syndrome	0.00029	0.00554	CbGeAlD
Sorafenib—CDK7—nervous system—epilepsy syndrome	0.00029	0.00554	CbGeAlD
Sorafenib—MKNK1—telencephalon—epilepsy syndrome	0.000287	0.00547	CbGeAlD
Sorafenib—AURKC—nervous system—epilepsy syndrome	0.000285	0.00545	CbGeAlD
Sorafenib—RALBP1—forebrain—epilepsy syndrome	0.000285	0.00545	CbGeAlD
Sorafenib—MAPK11—central nervous system—epilepsy syndrome	0.000284	0.00542	CbGeAlD
Sorafenib—RAF1—brainstem—epilepsy syndrome	0.000279	0.00534	CbGeAlD
Sorafenib—CDK7—central nervous system—epilepsy syndrome	0.000279	0.00533	CbGeAlD
Sorafenib—EPHA6—head—epilepsy syndrome	0.000279	0.00532	CbGeAlD
Sorafenib—MAPK11—cerebellum—epilepsy syndrome	0.000277	0.0053	CbGeAlD
Sorafenib—AURKC—central nervous system—epilepsy syndrome	0.000275	0.00525	CbGeAlD
Sorafenib—CDK7—cerebellum—epilepsy syndrome	0.000273	0.00521	CbGeAlD
Sorafenib—TAOK2—cerebellum—epilepsy syndrome	0.000271	0.00517	CbGeAlD
Sorafenib—RAF1—forebrain—epilepsy syndrome	0.00027	0.00515	CbGeAlD
Sorafenib—EPHB6—forebrain—epilepsy syndrome	0.000268	0.00512	CbGeAlD
Sorafenib—BRAF—midbrain—epilepsy syndrome	0.000267	0.0051	CbGeAlD
Sorafenib—EPHA6—nervous system—epilepsy syndrome	0.000264	0.00505	CbGeAlD
Sorafenib—ZAK—head—epilepsy syndrome	0.000264	0.00505	CbGeAlD
Sorafenib—RALBP1—telencephalon—epilepsy syndrome	0.000262	0.00501	CbGeAlD
Sorafenib—HIPK4—brain—epilepsy syndrome	0.000255	0.00488	CbGeAlD
Sorafenib—EPHA6—central nervous system—epilepsy syndrome	0.000254	0.00486	CbGeAlD
Sorafenib—PDGFRA—forebrain—epilepsy syndrome	0.000254	0.00485	CbGeAlD
Sorafenib—MAP3K19—head—epilepsy syndrome	0.000253	0.00484	CbGeAlD
Sorafenib—ZAK—nervous system—epilepsy syndrome	0.00025	0.00478	CbGeAlD
Sorafenib—FLT1—telencephalon—epilepsy syndrome	0.000249	0.00476	CbGeAlD
Sorafenib—FGFR1—medulla oblongata—epilepsy syndrome	0.000248	0.00475	CbGeAlD
Sorafenib—RAF1—telencephalon—epilepsy syndrome	0.000248	0.00473	CbGeAlD
Sorafenib—Regorafenib—ABCG2—epilepsy syndrome	0.000248	0.0726	CrCbGaD
Sorafenib—EPHB6—telencephalon—epilepsy syndrome	0.000246	0.00471	CbGeAlD
Sorafenib—TIE1—head—epilepsy syndrome	0.000242	0.00462	CbGeAlD
Sorafenib—ZAK—central nervous system—epilepsy syndrome	0.000241	0.00461	CbGeAlD
Sorafenib—MAP3K19—nervous system—epilepsy syndrome	0.00024	0.00459	CbGeAlD
Sorafenib—MAP2K5—brainstem—epilepsy syndrome	0.000237	0.00454	CbGeAlD
Sorafenib—ZAK—cerebellum—epilepsy syndrome	0.000236	0.0045	CbGeAlD
Sorafenib—MAP3K7—medulla oblongata—epilepsy syndrome	0.000235	0.00449	CbGeAlD
Sorafenib—PDGFRA—telencephalon—epilepsy syndrome	0.000234	0.00446	CbGeAlD
Sorafenib—MAP3K19—central nervous system—epilepsy syndrome	0.000231	0.00442	CbGeAlD
Sorafenib—HIPK3—cerebellum—epilepsy syndrome	0.000231	0.00441	CbGeAlD
Sorafenib—KDR—forebrain—epilepsy syndrome	0.000229	0.00438	CbGeAlD
Sorafenib—TIE1—nervous system—epilepsy syndrome	0.000229	0.00438	CbGeAlD
Sorafenib—MKNK2—medulla oblongata—epilepsy syndrome	0.000228	0.00436	CbGeAlD
Sorafenib—FGFR1—midbrain—epilepsy syndrome	0.000227	0.00434	CbGeAlD
Sorafenib—MKNK1—medulla oblongata—epilepsy syndrome	0.000225	0.0043	CbGeAlD
Sorafenib—MAPK11—brain—epilepsy syndrome	0.000225	0.0043	CbGeAlD
Sorafenib—CSF1R—forebrain—epilepsy syndrome	0.000224	0.00427	CbGeAlD
Sorafenib—RET—medulla oblongata—epilepsy syndrome	0.000222	0.00425	CbGeAlD
Sorafenib—FGFR1—spinal cord—epilepsy syndrome	0.000222	0.00423	CbGeAlD
Sorafenib—CDK7—brain—epilepsy syndrome	0.000221	0.00423	CbGeAlD
Sorafenib—TIE1—central nervous system—epilepsy syndrome	0.000221	0.00421	CbGeAlD
Sorafenib—TAOK2—brain—epilepsy syndrome	0.00022	0.0042	CbGeAlD
Sorafenib—AURKC—brain—epilepsy syndrome	0.000218	0.00417	CbGeAlD
Sorafenib—TIE1—cerebellum—epilepsy syndrome	0.000216	0.00412	CbGeAlD
Sorafenib—MAP3K7—midbrain—epilepsy syndrome	0.000215	0.00411	CbGeAlD
Sorafenib—MAP2K5—telencephalon—epilepsy syndrome	0.000211	0.00403	CbGeAlD
Sorafenib—KIT—brainstem—epilepsy syndrome	0.00021	0.00402	CbGeAlD
Sorafenib—MAP3K7—spinal cord—epilepsy syndrome	0.00021	0.00401	CbGeAlD
Sorafenib—MKNK2—midbrain—epilepsy syndrome	0.000208	0.00398	CbGeAlD
Sorafenib—BRAF—cerebellum—epilepsy syndrome	0.000207	0.00395	CbGeAlD
Sorafenib—RALBP1—medulla oblongata—epilepsy syndrome	0.000206	0.00393	CbGeAlD
Sorafenib—MKNK1—midbrain—epilepsy syndrome	0.000206	0.00393	CbGeAlD
Sorafenib—CSF1R—telencephalon—epilepsy syndrome	0.000206	0.00393	CbGeAlD
Sorafenib—MKNK2—spinal cord—epilepsy syndrome	0.000203	0.00388	CbGeAlD
Sorafenib—RET—midbrain—epilepsy syndrome	0.000203	0.00388	CbGeAlD
Sorafenib—EPHA6—brain—epilepsy syndrome	0.000202	0.00386	CbGeAlD
Sorafenib—MKNK1—spinal cord—epilepsy syndrome	0.000201	0.00384	CbGeAlD
Sorafenib—FLT4—head—epilepsy syndrome	0.0002	0.00381	CbGeAlD
Sorafenib—RET—spinal cord—epilepsy syndrome	0.000198	0.00379	CbGeAlD
Sorafenib—EPHX2—cerebellum—epilepsy syndrome	0.000197	0.00377	CbGeAlD
Sorafenib—Vismodegib—ABCG2—epilepsy syndrome	0.000196	0.0576	CrCbGaD
Sorafenib—FLT3—cerebellum—epilepsy syndrome	0.000196	0.00375	CbGeAlD
Sorafenib—FLT1—medulla oblongata—epilepsy syndrome	0.000196	0.00374	CbGeAlD
Sorafenib—RAF1—medulla oblongata—epilepsy syndrome	0.000195	0.00372	CbGeAlD
Sorafenib—Regorafenib—CYP2C19—epilepsy syndrome	0.000195	0.0571	CrCbGaD
Sorafenib—EPHB6—medulla oblongata—epilepsy syndrome	0.000194	0.0037	CbGeAlD
Sorafenib—ZAK—brain—epilepsy syndrome	0.000191	0.00366	CbGeAlD
Sorafenib—RALBP1—midbrain—epilepsy syndrome	0.000188	0.0036	CbGeAlD
Sorafenib—HIPK3—brain—epilepsy syndrome	0.000187	0.00358	CbGeAlD
Sorafenib—KIT—telencephalon—epilepsy syndrome	0.000187	0.00357	CbGeAlD
Sorafenib—RALBP1—spinal cord—epilepsy syndrome	0.000184	0.00351	CbGeAlD
Sorafenib—MAP3K19—brain—epilepsy syndrome	0.000184	0.00351	CbGeAlD
Sorafenib—PDGFRB—telencephalon—epilepsy syndrome	0.000182	0.00348	CbGeAlD
Sorafenib—MKNK2—head—epilepsy syndrome	0.000181	0.00345	CbGeAlD
Sorafenib—FLT1—midbrain—epilepsy syndrome	0.000179	0.00342	CbGeAlD
Sorafenib—MKNK1—head—epilepsy syndrome	0.000178	0.00341	CbGeAlD
Sorafenib—RAF1—midbrain—epilepsy syndrome	0.000178	0.0034	CbGeAlD
Sorafenib—EPHB6—midbrain—epilepsy syndrome	0.000177	0.00338	CbGeAlD
Sorafenib—RET—head—epilepsy syndrome	0.000176	0.00337	CbGeAlD
Sorafenib—FGFR1—cerebellum—epilepsy syndrome	0.000176	0.00336	CbGeAlD
Sorafenib—TIE1—brain—epilepsy syndrome	0.000175	0.00334	CbGeAlD
Sorafenib—FLT1—spinal cord—epilepsy syndrome	0.000175	0.00334	CbGeAlD
Sorafenib—RAF1—spinal cord—epilepsy syndrome	0.000174	0.00332	CbGeAlD
Sorafenib—HTR2C—brainstem—epilepsy syndrome	0.000173	0.00331	CbGeAlD
Sorafenib—EPHB6—spinal cord—epilepsy syndrome	0.000173	0.0033	CbGeAlD
Sorafenib—MKNK2—nervous system—epilepsy syndrome	0.000171	0.00327	CbGeAlD
Sorafenib—MKNK1—nervous system—epilepsy syndrome	0.000169	0.00323	CbGeAlD
Sorafenib—BRAF—brain—epilepsy syndrome	0.000168	0.00321	CbGeAlD
Sorafenib—HTR2C—forebrain—epilepsy syndrome	0.000167	0.0032	CbGeAlD
Sorafenib—RET—nervous system—epilepsy syndrome	0.000167	0.00319	CbGeAlD
Sorafenib—MAP3K7—cerebellum—epilepsy syndrome	0.000166	0.00318	CbGeAlD
Sorafenib—MAP2K5—medulla oblongata—epilepsy syndrome	0.000166	0.00316	CbGeAlD
Sorafenib—KDR—medulla oblongata—epilepsy syndrome	0.000166	0.00316	CbGeAlD
Sorafenib—MKNK2—central nervous system—epilepsy syndrome	0.000165	0.00315	CbGeAlD
Sorafenib—PDGFRA—spinal cord—epilepsy syndrome	0.000164	0.00313	CbGeAlD
Sorafenib—RALBP1—head—epilepsy syndrome	0.000163	0.00312	CbGeAlD
Sorafenib—MKNK1—central nervous system—epilepsy syndrome	0.000163	0.00311	CbGeAlD
Sorafenib—CSF1R—medulla oblongata—epilepsy syndrome	0.000162	0.00309	CbGeAlD
Sorafenib—MKNK2—cerebellum—epilepsy syndrome	0.000161	0.00308	CbGeAlD
Sorafenib—RET—central nervous system—epilepsy syndrome	0.000161	0.00307	CbGeAlD
Sorafenib—EPHX2—brain—epilepsy syndrome	0.00016	0.00306	CbGeAlD
Sorafenib—MKNK1—cerebellum—epilepsy syndrome	0.000159	0.00304	CbGeAlD
Sorafenib—ABCC4—forebrain—epilepsy syndrome	0.000158	0.00302	CbGeAlD
Sorafenib—RET—cerebellum—epilepsy syndrome	0.000157	0.003	CbGeAlD
Sorafenib—HTR2B—forebrain—epilepsy syndrome	0.000157	0.003	CbGeAlD
Sorafenib—FLT1—head—epilepsy syndrome	0.000155	0.00297	CbGeAlD
Sorafenib—RALBP1—nervous system—epilepsy syndrome	0.000155	0.00296	CbGeAlD
Sorafenib—Vismodegib—CYP2C19—epilepsy syndrome	0.000154	0.0453	CrCbGaD
Sorafenib—RAF1—head—epilepsy syndrome	0.000154	0.00295	CbGeAlD
Sorafenib—HTR2C—telencephalon—epilepsy syndrome	0.000154	0.00294	CbGeAlD
Sorafenib—EPHB6—head—epilepsy syndrome	0.000153	0.00293	CbGeAlD
Sorafenib—KDR—midbrain—epilepsy syndrome	0.000151	0.00289	CbGeAlD
Sorafenib—MAP2K5—midbrain—epilepsy syndrome	0.000151	0.00289	CbGeAlD
Sorafenib—RALBP1—central nervous system—epilepsy syndrome	0.000149	0.00285	CbGeAlD
Sorafenib—CSF1R—midbrain—epilepsy syndrome	0.000148	0.00282	CbGeAlD
Sorafenib—MAP2K5—spinal cord—epilepsy syndrome	0.000148	0.00282	CbGeAlD
Sorafenib—KDR—spinal cord—epilepsy syndrome	0.000148	0.00282	CbGeAlD
Sorafenib—FLT1—nervous system—epilepsy syndrome	0.000147	0.00281	CbGeAlD
Sorafenib—STK10—head—epilepsy syndrome	0.000147	0.00281	CbGeAlD
Sorafenib—KIT—medulla oblongata—epilepsy syndrome	0.000147	0.0028	CbGeAlD
Sorafenib—RAF1—nervous system—epilepsy syndrome	0.000146	0.0028	CbGeAlD
Sorafenib—RALBP1—cerebellum—epilepsy syndrome	0.000146	0.00278	CbGeAlD
Sorafenib—EPHB6—nervous system—epilepsy syndrome	0.000145	0.00278	CbGeAlD
Sorafenib—PDGFRA—head—epilepsy syndrome	0.000145	0.00278	CbGeAlD
Sorafenib—FLT4—brain—epilepsy syndrome	0.000145	0.00276	CbGeAlD
Sorafenib—HTR2B—telencephalon—epilepsy syndrome	0.000144	0.00276	CbGeAlD
Sorafenib—CSF1R—spinal cord—epilepsy syndrome	0.000144	0.00275	CbGeAlD
Sorafenib—PDGFRB—medulla oblongata—epilepsy syndrome	0.000143	0.00274	CbGeAlD
Sorafenib—FGFR1—brain—epilepsy syndrome	0.000143	0.00273	CbGeAlD
Sorafenib—FLT1—central nervous system—epilepsy syndrome	0.000142	0.00271	CbGeAlD
Sorafenib—RAF1—central nervous system—epilepsy syndrome	0.000141	0.00269	CbGeAlD
Sorafenib—EPHB6—central nervous system—epilepsy syndrome	0.00014	0.00268	CbGeAlD
Sorafenib—STK10—nervous system—epilepsy syndrome	0.000139	0.00266	CbGeAlD
Sorafenib—FLT1—cerebellum—epilepsy syndrome	0.000138	0.00265	CbGeAlD
Sorafenib—CYP2D6—hindbrain—epilepsy syndrome	0.000138	0.00264	CbGeAlD
Sorafenib—PDGFRA—nervous system—epilepsy syndrome	0.000138	0.00263	CbGeAlD
Sorafenib—RAF1—cerebellum—epilepsy syndrome	0.000138	0.00263	CbGeAlD
Sorafenib—EPHB6—cerebellum—epilepsy syndrome	0.000137	0.00262	CbGeAlD
Sorafenib—MAP3K7—brain—epilepsy syndrome	0.000135	0.00258	CbGeAlD
Sorafenib—STK10—central nervous system—epilepsy syndrome	0.000134	0.00256	CbGeAlD
Sorafenib—KIT—midbrain—epilepsy syndrome	0.000134	0.00256	CbGeAlD
Sorafenib—PDGFRA—central nervous system—epilepsy syndrome	0.000133	0.00254	CbGeAlD
Sorafenib—MAP2K5—head—epilepsy syndrome	0.000131	0.00251	CbGeAlD
Sorafenib—KDR—head—epilepsy syndrome	0.000131	0.00251	CbGeAlD
Sorafenib—STK10—cerebellum—epilepsy syndrome	0.000131	0.0025	CbGeAlD
Sorafenib—PDGFRB—midbrain—epilepsy syndrome	0.000131	0.0025	CbGeAlD
Sorafenib—MKNK2—brain—epilepsy syndrome	0.000131	0.0025	CbGeAlD
Sorafenib—KIT—spinal cord—epilepsy syndrome	0.000131	0.0025	CbGeAlD
Sorafenib—PDGFRA—cerebellum—epilepsy syndrome	0.00013	0.00248	CbGeAlD
Sorafenib—MKNK1—brain—epilepsy syndrome	0.000129	0.00247	CbGeAlD
Sorafenib—CSF1R—head—epilepsy syndrome	0.000128	0.00245	CbGeAlD
Sorafenib—PDGFRB—spinal cord—epilepsy syndrome	0.000128	0.00244	CbGeAlD
Sorafenib—RET—brain—epilepsy syndrome	0.000128	0.00244	CbGeAlD
Sorafenib—MAP2K5—nervous system—epilepsy syndrome	0.000124	0.00238	CbGeAlD
Sorafenib—KDR—nervous system—epilepsy syndrome	0.000124	0.00238	CbGeAlD
Sorafenib—CSF1R—nervous system—epilepsy syndrome	0.000121	0.00232	CbGeAlD
Sorafenib—HTR2C—medulla oblongata—epilepsy syndrome	0.000121	0.00231	CbGeAlD
Sorafenib—KDR—central nervous system—epilepsy syndrome	0.00012	0.00229	CbGeAlD
Sorafenib—MAP2K5—central nervous system—epilepsy syndrome	0.00012	0.00229	CbGeAlD
Sorafenib—RALBP1—brain—epilepsy syndrome	0.000118	0.00226	CbGeAlD
Sorafenib—KDR—cerebellum—epilepsy syndrome	0.000117	0.00224	CbGeAlD
Sorafenib—MAP2K5—cerebellum—epilepsy syndrome	0.000117	0.00224	CbGeAlD
Sorafenib—CSF1R—central nervous system—epilepsy syndrome	0.000117	0.00223	CbGeAlD
Sorafenib—KIT—head—epilepsy syndrome	0.000116	0.00222	CbGeAlD
Sorafenib—CSF1R—cerebellum—epilepsy syndrome	0.000114	0.00218	CbGeAlD
Sorafenib—PDGFRB—head—epilepsy syndrome	0.000114	0.00217	CbGeAlD
Sorafenib—FLT1—brain—epilepsy syndrome	0.000112	0.00215	CbGeAlD
Sorafenib—RAF1—brain—epilepsy syndrome	0.000112	0.00214	CbGeAlD
Sorafenib—EPHB6—brain—epilepsy syndrome	0.000111	0.00212	CbGeAlD
Sorafenib—HTR2C—midbrain—epilepsy syndrome	0.00011	0.00211	CbGeAlD
Sorafenib—KIT—nervous system—epilepsy syndrome	0.00011	0.00211	CbGeAlD
Sorafenib—HTR2C—spinal cord—epilepsy syndrome	0.000108	0.00206	CbGeAlD
Sorafenib—PDGFRB—nervous system—epilepsy syndrome	0.000108	0.00206	CbGeAlD
Sorafenib—STK10—brain—epilepsy syndrome	0.000106	0.00203	CbGeAlD
Sorafenib—KIT—central nervous system—epilepsy syndrome	0.000106	0.00203	CbGeAlD
Sorafenib—PDGFRA—brain—epilepsy syndrome	0.000105	0.00201	CbGeAlD
Sorafenib—KIT—cerebellum—epilepsy syndrome	0.000104	0.00198	CbGeAlD
Sorafenib—PDGFRB—central nervous system—epilepsy syndrome	0.000104	0.00198	CbGeAlD
Sorafenib—Regorafenib—ABCB1—epilepsy syndrome	0.000103	0.0302	CrCbGaD
Sorafenib—ABCG2—telencephalon—epilepsy syndrome	0.000103	0.00196	CbGeAlD
Sorafenib—PDGFRB—cerebellum—epilepsy syndrome	0.000101	0.00194	CbGeAlD
Sorafenib—HTR2C—head—epilepsy syndrome	9.58e-05	0.00183	CbGeAlD
Sorafenib—MAP2K5—brain—epilepsy syndrome	9.51e-05	0.00182	CbGeAlD
Sorafenib—KDR—brain—epilepsy syndrome	9.51e-05	0.00182	CbGeAlD
Sorafenib—CSF1R—brain—epilepsy syndrome	9.28e-05	0.00177	CbGeAlD
Sorafenib—HTR2C—nervous system—epilepsy syndrome	9.08e-05	0.00173	CbGeAlD
Sorafenib—ABCC4—head—epilepsy syndrome	9.04e-05	0.00173	CbGeAlD
Sorafenib—HTR2B—head—epilepsy syndrome	8.99e-05	0.00172	CbGeAlD
Sorafenib—HTR2C—central nervous system—epilepsy syndrome	8.74e-05	0.00167	CbGeAlD
Sorafenib—ABCC4—nervous system—epilepsy syndrome	8.57e-05	0.00164	CbGeAlD
Sorafenib—Vismodegib—ALB—epilepsy syndrome	8.56e-05	0.0251	CrCbGaD
Sorafenib—HTR2B—nervous system—epilepsy syndrome	8.53e-05	0.00163	CbGeAlD
Sorafenib—KIT—brain—epilepsy syndrome	8.43e-05	0.00161	CbGeAlD
Sorafenib—ABCC4—central nervous system—epilepsy syndrome	8.25e-05	0.00158	CbGeAlD
Sorafenib—PDGFRB—brain—epilepsy syndrome	8.23e-05	0.00157	CbGeAlD
Sorafenib—HTR2B—central nervous system—epilepsy syndrome	8.21e-05	0.00157	CbGeAlD
Sorafenib—Vismodegib—ABCB1—epilepsy syndrome	8.17e-05	0.024	CrCbGaD
Sorafenib—ABCG2—medulla oblongata—epilepsy syndrome	8.05e-05	0.00154	CbGeAlD
Sorafenib—CYP2D6—brainstem—epilepsy syndrome	7.92e-05	0.00151	CbGeAlD
Sorafenib—CYP2D6—forebrain—epilepsy syndrome	7.64e-05	0.00146	CbGeAlD
Sorafenib—ABCG2—midbrain—epilepsy syndrome	7.36e-05	0.00141	CbGeAlD
Sorafenib—ABCG2—spinal cord—epilepsy syndrome	7.18e-05	0.00137	CbGeAlD
Sorafenib—CYP2D6—telencephalon—epilepsy syndrome	7.03e-05	0.00134	CbGeAlD
Sorafenib—HTR2C—brain—epilepsy syndrome	6.94e-05	0.00133	CbGeAlD
Sorafenib—ABCC4—brain—epilepsy syndrome	6.55e-05	0.00125	CbGeAlD
Sorafenib—HTR2B—brain—epilepsy syndrome	6.52e-05	0.00125	CbGeAlD
Sorafenib—CYP2B6—head—epilepsy syndrome	5.89e-05	0.00113	CbGeAlD
Sorafenib—ABCG2—cerebellum—epilepsy syndrome	5.69e-05	0.00109	CbGeAlD
Sorafenib—CYP2B6—nervous system—epilepsy syndrome	5.58e-05	0.00107	CbGeAlD
Sorafenib—ABCB1—forebrain—epilepsy syndrome	5.5e-05	0.00105	CbGeAlD
Sorafenib—CYP2B6—central nervous system—epilepsy syndrome	5.38e-05	0.00103	CbGeAlD
Sorafenib—ABCB1—telencephalon—epilepsy syndrome	5.05e-05	0.000966	CbGeAlD
Sorafenib—CYP2C8—brain—epilepsy syndrome	4.76e-05	0.000909	CbGeAlD
Sorafenib—ABCG2—brain—epilepsy syndrome	4.63e-05	0.000884	CbGeAlD
Sorafenib—CYP2D6—head—epilepsy syndrome	4.38e-05	0.000836	CbGeAlD
Sorafenib—CYP2B6—brain—epilepsy syndrome	4.27e-05	0.000815	CbGeAlD
Sorafenib—CYP3A4—nervous system—epilepsy syndrome	4.22e-05	0.000805	CbGeAlD
Sorafenib—CYP2D6—nervous system—epilepsy syndrome	4.15e-05	0.000793	CbGeAlD
Sorafenib—CYP3A4—central nervous system—epilepsy syndrome	4.06e-05	0.000776	CbGeAlD
Sorafenib—CYP2D6—central nervous system—epilepsy syndrome	3.99e-05	0.000763	CbGeAlD
Sorafenib—ABCB1—medulla oblongata—epilepsy syndrome	3.97e-05	0.000759	CbGeAlD
Sorafenib—CYP2D6—cerebellum—epilepsy syndrome	3.9e-05	0.000746	CbGeAlD
Sorafenib—Dizziness—Vigabatrin—epilepsy syndrome	3.83e-05	0.000325	CcSEcCtD
Sorafenib—Pruritus—Zonisamide—epilepsy syndrome	3.82e-05	0.000324	CcSEcCtD
Sorafenib—Hypersensitivity—Phenytoin—epilepsy syndrome	3.81e-05	0.000323	CcSEcCtD
Sorafenib—Anaphylactic shock—Valproic Acid—epilepsy syndrome	3.79e-05	0.000321	CcSEcCtD
Sorafenib—Urticaria—Lamotrigine—epilepsy syndrome	3.79e-05	0.000321	CcSEcCtD
Sorafenib—Hypersensitivity—Oxcarbazepine—epilepsy syndrome	3.79e-05	0.000321	CcSEcCtD
Sorafenib—Nausea—Propofol—epilepsy syndrome	3.78e-05	0.000321	CcSEcCtD
Sorafenib—Vomiting—Fosphenytoin—epilepsy syndrome	3.78e-05	0.00032	CcSEcCtD
Sorafenib—Diarrhoea—Felbamate—epilepsy syndrome	3.78e-05	0.00032	CcSEcCtD
Sorafenib—Abdominal pain—Lamotrigine—epilepsy syndrome	3.77e-05	0.00032	CcSEcCtD
Sorafenib—Body temperature increased—Lamotrigine—epilepsy syndrome	3.77e-05	0.00032	CcSEcCtD
Sorafenib—Dysgeusia—Gabapentin—epilepsy syndrome	3.77e-05	0.00032	CcSEcCtD
Sorafenib—Dizziness—Diazepam—epilepsy syndrome	3.77e-05	0.00032	CcSEcCtD
Sorafenib—Infection—Valproic Acid—epilepsy syndrome	3.77e-05	0.000319	CcSEcCtD
Sorafenib—Syncope—Pregabalin—epilepsy syndrome	3.77e-05	0.000319	CcSEcCtD
Sorafenib—Leukopenia—Pregabalin—epilepsy syndrome	3.76e-05	0.000319	CcSEcCtD
Sorafenib—Rash—Fosphenytoin—epilepsy syndrome	3.75e-05	0.000318	CcSEcCtD
Sorafenib—Dermatitis—Fosphenytoin—epilepsy syndrome	3.74e-05	0.000317	CcSEcCtD
Sorafenib—Haemoglobin—Topiramate—epilepsy syndrome	3.74e-05	0.000317	CcSEcCtD
Sorafenib—Asthenia—Clonazepam—epilepsy syndrome	3.74e-05	0.000317	CcSEcCtD
Sorafenib—Headache—Fosphenytoin—epilepsy syndrome	3.72e-05	0.000316	CcSEcCtD
Sorafenib—Haemorrhage—Topiramate—epilepsy syndrome	3.72e-05	0.000316	CcSEcCtD
Sorafenib—Nervous system disorder—Valproic Acid—epilepsy syndrome	3.72e-05	0.000315	CcSEcCtD
Sorafenib—Thrombocytopenia—Valproic Acid—epilepsy syndrome	3.71e-05	0.000315	CcSEcCtD
Sorafenib—Asthenia—Phenytoin—epilepsy syndrome	3.71e-05	0.000315	CcSEcCtD
Sorafenib—Nausea—Midazolam—epilepsy syndrome	3.7e-05	0.000314	CcSEcCtD
Sorafenib—Muscle spasms—Gabapentin—epilepsy syndrome	3.7e-05	0.000314	CcSEcCtD
Sorafenib—Diarrhoea—Zonisamide—epilepsy syndrome	3.7e-05	0.000313	CcSEcCtD
Sorafenib—Loss of consciousness—Pregabalin—epilepsy syndrome	3.69e-05	0.000313	CcSEcCtD
Sorafenib—Asthenia—Oxcarbazepine—epilepsy syndrome	3.69e-05	0.000313	CcSEcCtD
Sorafenib—Pruritus—Clonazepam—epilepsy syndrome	3.68e-05	0.000312	CcSEcCtD
Sorafenib—Vomiting—Vigabatrin—epilepsy syndrome	3.68e-05	0.000312	CcSEcCtD
Sorafenib—Skin disorder—Valproic Acid—epilepsy syndrome	3.68e-05	0.000312	CcSEcCtD
Sorafenib—Urinary tract disorder—Topiramate—epilepsy syndrome	3.68e-05	0.000312	CcSEcCtD
Sorafenib—Cough—Pregabalin—epilepsy syndrome	3.66e-05	0.000311	CcSEcCtD
Sorafenib—Pruritus—Phenytoin—epilepsy syndrome	3.66e-05	0.00031	CcSEcCtD
Sorafenib—Connective tissue disorder—Topiramate—epilepsy syndrome	3.66e-05	0.00031	CcSEcCtD
Sorafenib—Nausea—Levetiracetam—epilepsy syndrome	3.66e-05	0.00031	CcSEcCtD
Sorafenib—Rash—Vigabatrin—epilepsy syndrome	3.65e-05	0.00031	CcSEcCtD
Sorafenib—Dizziness—Felbamate—epilepsy syndrome	3.65e-05	0.000309	CcSEcCtD
Sorafenib—Dermatitis—Vigabatrin—epilepsy syndrome	3.65e-05	0.000309	CcSEcCtD
Sorafenib—Urethral disorder—Topiramate—epilepsy syndrome	3.65e-05	0.000309	CcSEcCtD
Sorafenib—Pruritus—Oxcarbazepine—epilepsy syndrome	3.64e-05	0.000309	CcSEcCtD
Sorafenib—Hypersensitivity—Carbamazepine—epilepsy syndrome	3.64e-05	0.000308	CcSEcCtD
Sorafenib—ABCB1—midbrain—epilepsy syndrome	3.63e-05	0.000694	CbGeAlD
Sorafenib—Headache—Vigabatrin—epilepsy syndrome	3.63e-05	0.000308	CcSEcCtD
Sorafenib—Hypertension—Pregabalin—epilepsy syndrome	3.63e-05	0.000307	CcSEcCtD
Sorafenib—Vomiting—Diazepam—epilepsy syndrome	3.63e-05	0.000307	CcSEcCtD
Sorafenib—Anorexia—Valproic Acid—epilepsy syndrome	3.61e-05	0.000306	CcSEcCtD
Sorafenib—Rash—Diazepam—epilepsy syndrome	3.6e-05	0.000305	CcSEcCtD
Sorafenib—Dermatitis—Diazepam—epilepsy syndrome	3.59e-05	0.000305	CcSEcCtD
Sorafenib—Myalgia—Pregabalin—epilepsy syndrome	3.58e-05	0.000303	CcSEcCtD
Sorafenib—Arthralgia—Pregabalin—epilepsy syndrome	3.58e-05	0.000303	CcSEcCtD
Sorafenib—Dizziness—Zonisamide—epilepsy syndrome	3.57e-05	0.000303	CcSEcCtD
Sorafenib—Headache—Diazepam—epilepsy syndrome	3.57e-05	0.000303	CcSEcCtD
Sorafenib—Diarrhoea—Clonazepam—epilepsy syndrome	3.56e-05	0.000302	CcSEcCtD
Sorafenib—Anaemia—Gabapentin—epilepsy syndrome	3.56e-05	0.000302	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	3.55e-05	0.000301	CcSEcCtD
Sorafenib—ABCB1—spinal cord—epilepsy syndrome	3.54e-05	0.000677	CbGeAlD
Sorafenib—Asthenia—Carbamazepine—epilepsy syndrome	3.54e-05	0.0003	CcSEcCtD
Sorafenib—Diarrhoea—Phenytoin—epilepsy syndrome	3.54e-05	0.0003	CcSEcCtD
Sorafenib—Nausea—Fosphenytoin—epilepsy syndrome	3.53e-05	0.000299	CcSEcCtD
Sorafenib—Diarrhoea—Oxcarbazepine—epilepsy syndrome	3.52e-05	0.000298	CcSEcCtD
Sorafenib—Erythema multiforme—Topiramate—epilepsy syndrome	3.52e-05	0.000298	CcSEcCtD
Sorafenib—Angioedema—Gabapentin—epilepsy syndrome	3.52e-05	0.000298	CcSEcCtD
Sorafenib—Hypersensitivity—Lamotrigine—epilepsy syndrome	3.51e-05	0.000298	CcSEcCtD
Sorafenib—Vomiting—Felbamate—epilepsy syndrome	3.51e-05	0.000298	CcSEcCtD
Sorafenib—Dry mouth—Pregabalin—epilepsy syndrome	3.5e-05	0.000296	CcSEcCtD
Sorafenib—Pruritus—Carbamazepine—epilepsy syndrome	3.49e-05	0.000296	CcSEcCtD
Sorafenib—Rash—Felbamate—epilepsy syndrome	3.48e-05	0.000295	CcSEcCtD
Sorafenib—Dermatitis—Felbamate—epilepsy syndrome	3.48e-05	0.000295	CcSEcCtD
Sorafenib—Tinnitus—Topiramate—epilepsy syndrome	3.47e-05	0.000294	CcSEcCtD
Sorafenib—Headache—Felbamate—epilepsy syndrome	3.46e-05	0.000293	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	3.45e-05	0.000293	CcSEcCtD
Sorafenib—Flushing—Topiramate—epilepsy syndrome	3.45e-05	0.000293	CcSEcCtD
Sorafenib—Cardiac disorder—Topiramate—epilepsy syndrome	3.45e-05	0.000293	CcSEcCtD
Sorafenib—Syncope—Gabapentin—epilepsy syndrome	3.45e-05	0.000293	CcSEcCtD
Sorafenib—Leukopenia—Gabapentin—epilepsy syndrome	3.45e-05	0.000292	CcSEcCtD
Sorafenib—Dizziness—Clonazepam—epilepsy syndrome	3.44e-05	0.000292	CcSEcCtD
Sorafenib—Nausea—Vigabatrin—epilepsy syndrome	3.44e-05	0.000292	CcSEcCtD
Sorafenib—Vomiting—Zonisamide—epilepsy syndrome	3.43e-05	0.000291	CcSEcCtD
Sorafenib—Anaphylactic shock—Pregabalin—epilepsy syndrome	3.43e-05	0.000291	CcSEcCtD
Sorafenib—Asthenia—Lamotrigine—epilepsy syndrome	3.42e-05	0.00029	CcSEcCtD
Sorafenib—Dizziness—Phenytoin—epilepsy syndrome	3.42e-05	0.00029	CcSEcCtD
Sorafenib—Rash—Zonisamide—epilepsy syndrome	3.41e-05	0.000289	CcSEcCtD
Sorafenib—Infection—Pregabalin—epilepsy syndrome	3.4e-05	0.000289	CcSEcCtD
Sorafenib—Dermatitis—Zonisamide—epilepsy syndrome	3.4e-05	0.000289	CcSEcCtD
Sorafenib—Dizziness—Oxcarbazepine—epilepsy syndrome	3.4e-05	0.000288	CcSEcCtD
Sorafenib—Nausea—Diazepam—epilepsy syndrome	3.39e-05	0.000287	CcSEcCtD
Sorafenib—Loss of consciousness—Gabapentin—epilepsy syndrome	3.38e-05	0.000287	CcSEcCtD
Sorafenib—Headache—Zonisamide—epilepsy syndrome	3.38e-05	0.000287	CcSEcCtD
Sorafenib—Dyspnoea—Valproic Acid—epilepsy syndrome	3.38e-05	0.000287	CcSEcCtD
Sorafenib—Diarrhoea—Carbamazepine—epilepsy syndrome	3.38e-05	0.000286	CcSEcCtD
Sorafenib—Angiopathy—Topiramate—epilepsy syndrome	3.38e-05	0.000286	CcSEcCtD
Sorafenib—Pruritus—Lamotrigine—epilepsy syndrome	3.38e-05	0.000286	CcSEcCtD
Sorafenib—Shock—Pregabalin—epilepsy syndrome	3.37e-05	0.000286	CcSEcCtD
Sorafenib—Immune system disorder—Topiramate—epilepsy syndrome	3.36e-05	0.000285	CcSEcCtD
Sorafenib—Nervous system disorder—Pregabalin—epilepsy syndrome	3.36e-05	0.000285	CcSEcCtD
Sorafenib—Cough—Gabapentin—epilepsy syndrome	3.36e-05	0.000285	CcSEcCtD
Sorafenib—Thrombocytopenia—Pregabalin—epilepsy syndrome	3.36e-05	0.000285	CcSEcCtD
Sorafenib—Mediastinal disorder—Topiramate—epilepsy syndrome	3.35e-05	0.000284	CcSEcCtD
Sorafenib—Dyspepsia—Valproic Acid—epilepsy syndrome	3.34e-05	0.000283	CcSEcCtD
Sorafenib—Skin disorder—Pregabalin—epilepsy syndrome	3.33e-05	0.000282	CcSEcCtD
Sorafenib—Hypertension—Gabapentin—epilepsy syndrome	3.32e-05	0.000282	CcSEcCtD
Sorafenib—Vomiting—Clonazepam—epilepsy syndrome	3.31e-05	0.000281	CcSEcCtD
Sorafenib—Decreased appetite—Valproic Acid—epilepsy syndrome	3.3e-05	0.000279	CcSEcCtD
Sorafenib—Alopecia—Topiramate—epilepsy syndrome	3.29e-05	0.000279	CcSEcCtD
Sorafenib—Vomiting—Phenytoin—epilepsy syndrome	3.29e-05	0.000279	CcSEcCtD
Sorafenib—Rash—Clonazepam—epilepsy syndrome	3.28e-05	0.000278	CcSEcCtD
Sorafenib—Dermatitis—Clonazepam—epilepsy syndrome	3.28e-05	0.000278	CcSEcCtD
Sorafenib—Arthralgia—Gabapentin—epilepsy syndrome	3.28e-05	0.000278	CcSEcCtD
Sorafenib—Myalgia—Gabapentin—epilepsy syndrome	3.28e-05	0.000278	CcSEcCtD
Sorafenib—Nausea—Felbamate—epilepsy syndrome	3.28e-05	0.000278	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	3.27e-05	0.000278	CcSEcCtD
Sorafenib—Vomiting—Oxcarbazepine—epilepsy syndrome	3.27e-05	0.000277	CcSEcCtD
Sorafenib—Fatigue—Valproic Acid—epilepsy syndrome	3.27e-05	0.000277	CcSEcCtD
Sorafenib—Anorexia—Pregabalin—epilepsy syndrome	3.27e-05	0.000277	CcSEcCtD
Sorafenib—Dizziness—Carbamazepine—epilepsy syndrome	3.26e-05	0.000277	CcSEcCtD
Sorafenib—Diarrhoea—Lamotrigine—epilepsy syndrome	3.26e-05	0.000277	CcSEcCtD
Sorafenib—Headache—Clonazepam—epilepsy syndrome	3.26e-05	0.000277	CcSEcCtD
Sorafenib—Rash—Phenytoin—epilepsy syndrome	3.26e-05	0.000276	CcSEcCtD
Sorafenib—Mental disorder—Topiramate—epilepsy syndrome	3.26e-05	0.000276	CcSEcCtD
Sorafenib—Dermatitis—Phenytoin—epilepsy syndrome	3.26e-05	0.000276	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	3.26e-05	0.000276	CcSEcCtD
Sorafenib—Rash—Oxcarbazepine—epilepsy syndrome	3.24e-05	0.000275	CcSEcCtD
Sorafenib—Constipation—Valproic Acid—epilepsy syndrome	3.24e-05	0.000275	CcSEcCtD
Sorafenib—Pain—Valproic Acid—epilepsy syndrome	3.24e-05	0.000275	CcSEcCtD
Sorafenib—Dermatitis—Oxcarbazepine—epilepsy syndrome	3.24e-05	0.000275	CcSEcCtD
Sorafenib—Headache—Phenytoin—epilepsy syndrome	3.24e-05	0.000275	CcSEcCtD
Sorafenib—Malnutrition—Topiramate—epilepsy syndrome	3.24e-05	0.000275	CcSEcCtD
Sorafenib—Erythema—Topiramate—epilepsy syndrome	3.24e-05	0.000275	CcSEcCtD
Sorafenib—Headache—Oxcarbazepine—epilepsy syndrome	3.22e-05	0.000273	CcSEcCtD
Sorafenib—Nausea—Zonisamide—epilepsy syndrome	3.21e-05	0.000272	CcSEcCtD
Sorafenib—Dry mouth—Gabapentin—epilepsy syndrome	3.21e-05	0.000272	CcSEcCtD
Sorafenib—Dysgeusia—Topiramate—epilepsy syndrome	3.17e-05	0.000269	CcSEcCtD
Sorafenib—CYP2D6—brain—epilepsy syndrome	3.17e-05	0.000606	CbGeAlD
Sorafenib—Dizziness—Lamotrigine—epilepsy syndrome	3.15e-05	0.000267	CcSEcCtD
Sorafenib—ABCB1—head—epilepsy syndrome	3.15e-05	0.000601	CbGeAlD
Sorafenib—Anaphylactic shock—Gabapentin—epilepsy syndrome	3.14e-05	0.000266	CcSEcCtD
Sorafenib—Vomiting—Carbamazepine—epilepsy syndrome	3.14e-05	0.000266	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	3.12e-05	0.000265	CcSEcCtD
Sorafenib—Infection—Gabapentin—epilepsy syndrome	3.12e-05	0.000265	CcSEcCtD
Sorafenib—Muscle spasms—Topiramate—epilepsy syndrome	3.11e-05	0.000264	CcSEcCtD
Sorafenib—Rash—Carbamazepine—epilepsy syndrome	3.11e-05	0.000264	CcSEcCtD
Sorafenib—Dermatitis—Carbamazepine—epilepsy syndrome	3.11e-05	0.000264	CcSEcCtD
Sorafenib—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	3.1e-05	0.000263	CcSEcCtD
Sorafenib—Nausea—Clonazepam—epilepsy syndrome	3.09e-05	0.000262	CcSEcCtD
Sorafenib—Headache—Carbamazepine—epilepsy syndrome	3.09e-05	0.000262	CcSEcCtD
Sorafenib—Shock—Gabapentin—epilepsy syndrome	3.09e-05	0.000262	CcSEcCtD
Sorafenib—Nervous system disorder—Gabapentin—epilepsy syndrome	3.08e-05	0.000261	CcSEcCtD
Sorafenib—Thrombocytopenia—Gabapentin—epilepsy syndrome	3.08e-05	0.000261	CcSEcCtD
Sorafenib—Nausea—Phenytoin—epilepsy syndrome	3.07e-05	0.00026	CcSEcCtD
Sorafenib—Dyspnoea—Pregabalin—epilepsy syndrome	3.06e-05	0.000259	CcSEcCtD
Sorafenib—Nausea—Oxcarbazepine—epilepsy syndrome	3.06e-05	0.000259	CcSEcCtD
Sorafenib—Skin disorder—Gabapentin—epilepsy syndrome	3.05e-05	0.000259	CcSEcCtD
Sorafenib—Vomiting—Lamotrigine—epilepsy syndrome	3.03e-05	0.000257	CcSEcCtD
Sorafenib—Urticaria—Valproic Acid—epilepsy syndrome	3.01e-05	0.000255	CcSEcCtD
Sorafenib—Rash—Lamotrigine—epilepsy syndrome	3.01e-05	0.000255	CcSEcCtD
Sorafenib—Dermatitis—Lamotrigine—epilepsy syndrome	3.01e-05	0.000255	CcSEcCtD
Sorafenib—Abdominal pain—Valproic Acid—epilepsy syndrome	3e-05	0.000254	CcSEcCtD
Sorafenib—Body temperature increased—Valproic Acid—epilepsy syndrome	3e-05	0.000254	CcSEcCtD
Sorafenib—Anorexia—Gabapentin—epilepsy syndrome	3e-05	0.000254	CcSEcCtD
Sorafenib—Anaemia—Topiramate—epilepsy syndrome	2.99e-05	0.000254	CcSEcCtD
Sorafenib—Headache—Lamotrigine—epilepsy syndrome	2.99e-05	0.000253	CcSEcCtD
Sorafenib—ABCB1—nervous system—epilepsy syndrome	2.98e-05	0.00057	CbGeAlD
Sorafenib—Decreased appetite—Pregabalin—epilepsy syndrome	2.98e-05	0.000253	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	2.96e-05	0.000251	CcSEcCtD
Sorafenib—Fatigue—Pregabalin—epilepsy syndrome	2.95e-05	0.000251	CcSEcCtD
Sorafenib—Nausea—Carbamazepine—epilepsy syndrome	2.93e-05	0.000249	CcSEcCtD
Sorafenib—Constipation—Pregabalin—epilepsy syndrome	2.93e-05	0.000249	CcSEcCtD
Sorafenib—Pain—Pregabalin—epilepsy syndrome	2.93e-05	0.000249	CcSEcCtD
Sorafenib—Syncope—Topiramate—epilepsy syndrome	2.91e-05	0.000246	CcSEcCtD
Sorafenib—Leukopenia—Topiramate—epilepsy syndrome	2.9e-05	0.000246	CcSEcCtD
Sorafenib—ABCB1—central nervous system—epilepsy syndrome	2.87e-05	0.000549	CbGeAlD
Sorafenib—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	2.86e-05	0.000243	CcSEcCtD
Sorafenib—Loss of consciousness—Topiramate—epilepsy syndrome	2.85e-05	0.000241	CcSEcCtD
Sorafenib—Nausea—Lamotrigine—epilepsy syndrome	2.83e-05	0.00024	CcSEcCtD
Sorafenib—Cough—Topiramate—epilepsy syndrome	2.83e-05	0.00024	CcSEcCtD
Sorafenib—ABCB1—cerebellum—epilepsy syndrome	2.81e-05	0.000537	CbGeAlD
Sorafenib—Gastrointestinal pain—Pregabalin—epilepsy syndrome	2.8e-05	0.000238	CcSEcCtD
Sorafenib—Dyspnoea—Gabapentin—epilepsy syndrome	2.8e-05	0.000238	CcSEcCtD
Sorafenib—Hypertension—Topiramate—epilepsy syndrome	2.8e-05	0.000237	CcSEcCtD
Sorafenib—Hypersensitivity—Valproic Acid—epilepsy syndrome	2.79e-05	0.000237	CcSEcCtD
Sorafenib—Dyspepsia—Gabapentin—epilepsy syndrome	2.77e-05	0.000235	CcSEcCtD
Sorafenib—Arthralgia—Topiramate—epilepsy syndrome	2.76e-05	0.000234	CcSEcCtD
Sorafenib—Myalgia—Topiramate—epilepsy syndrome	2.76e-05	0.000234	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	2.74e-05	0.000232	CcSEcCtD
Sorafenib—Decreased appetite—Gabapentin—epilepsy syndrome	2.73e-05	0.000232	CcSEcCtD
Sorafenib—Urticaria—Pregabalin—epilepsy syndrome	2.72e-05	0.000231	CcSEcCtD
Sorafenib—Asthenia—Valproic Acid—epilepsy syndrome	2.72e-05	0.000231	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	2.71e-05	0.00023	CcSEcCtD
Sorafenib—Fatigue—Gabapentin—epilepsy syndrome	2.71e-05	0.00023	CcSEcCtD
Sorafenib—Abdominal pain—Pregabalin—epilepsy syndrome	2.71e-05	0.00023	CcSEcCtD
Sorafenib—Body temperature increased—Pregabalin—epilepsy syndrome	2.71e-05	0.00023	CcSEcCtD
Sorafenib—Dry mouth—Topiramate—epilepsy syndrome	2.7e-05	0.000229	CcSEcCtD
Sorafenib—Constipation—Gabapentin—epilepsy syndrome	2.69e-05	0.000228	CcSEcCtD
Sorafenib—Pain—Gabapentin—epilepsy syndrome	2.69e-05	0.000228	CcSEcCtD
Sorafenib—Pruritus—Valproic Acid—epilepsy syndrome	2.68e-05	0.000227	CcSEcCtD
Sorafenib—Infection—Topiramate—epilepsy syndrome	2.63e-05	0.000223	CcSEcCtD
Sorafenib—Shock—Topiramate—epilepsy syndrome	2.6e-05	0.000221	CcSEcCtD
Sorafenib—Diarrhoea—Valproic Acid—epilepsy syndrome	2.59e-05	0.00022	CcSEcCtD
Sorafenib—Nervous system disorder—Topiramate—epilepsy syndrome	2.59e-05	0.00022	CcSEcCtD
Sorafenib—Thrombocytopenia—Topiramate—epilepsy syndrome	2.59e-05	0.00022	CcSEcCtD
Sorafenib—Gastrointestinal pain—Gabapentin—epilepsy syndrome	2.57e-05	0.000218	CcSEcCtD
Sorafenib—Skin disorder—Topiramate—epilepsy syndrome	2.57e-05	0.000218	CcSEcCtD
Sorafenib—Hypersensitivity—Pregabalin—epilepsy syndrome	2.52e-05	0.000214	CcSEcCtD
Sorafenib—Anorexia—Topiramate—epilepsy syndrome	2.52e-05	0.000214	CcSEcCtD
Sorafenib—Dizziness—Valproic Acid—epilepsy syndrome	2.51e-05	0.000213	CcSEcCtD
Sorafenib—Urticaria—Gabapentin—epilepsy syndrome	2.5e-05	0.000212	CcSEcCtD
Sorafenib—Abdominal pain—Gabapentin—epilepsy syndrome	2.48e-05	0.000211	CcSEcCtD
Sorafenib—Body temperature increased—Gabapentin—epilepsy syndrome	2.48e-05	0.000211	CcSEcCtD
Sorafenib—Asthenia—Pregabalin—epilepsy syndrome	2.46e-05	0.000208	CcSEcCtD
Sorafenib—Pruritus—Pregabalin—epilepsy syndrome	2.42e-05	0.000206	CcSEcCtD
Sorafenib—Vomiting—Valproic Acid—epilepsy syndrome	2.41e-05	0.000204	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	2.41e-05	0.000204	CcSEcCtD
Sorafenib—Rash—Valproic Acid—epilepsy syndrome	2.39e-05	0.000203	CcSEcCtD
Sorafenib—Dermatitis—Valproic Acid—epilepsy syndrome	2.39e-05	0.000202	CcSEcCtD
Sorafenib—Headache—Valproic Acid—epilepsy syndrome	2.37e-05	0.000201	CcSEcCtD
Sorafenib—Dyspnoea—Topiramate—epilepsy syndrome	2.36e-05	0.0002	CcSEcCtD
Sorafenib—Diarrhoea—Pregabalin—epilepsy syndrome	2.34e-05	0.000199	CcSEcCtD
Sorafenib—Dyspepsia—Topiramate—epilepsy syndrome	2.33e-05	0.000197	CcSEcCtD
Sorafenib—Hypersensitivity—Gabapentin—epilepsy syndrome	2.32e-05	0.000196	CcSEcCtD
Sorafenib—Decreased appetite—Topiramate—epilepsy syndrome	2.3e-05	0.000195	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Topiramate—epilepsy syndrome	2.28e-05	0.000194	CcSEcCtD
Sorafenib—ABCB1—brain—epilepsy syndrome	2.28e-05	0.000436	CbGeAlD
Sorafenib—Fatigue—Topiramate—epilepsy syndrome	2.28e-05	0.000193	CcSEcCtD
Sorafenib—Dizziness—Pregabalin—epilepsy syndrome	2.27e-05	0.000192	CcSEcCtD
Sorafenib—Pain—Topiramate—epilepsy syndrome	2.26e-05	0.000192	CcSEcCtD
Sorafenib—Constipation—Topiramate—epilepsy syndrome	2.26e-05	0.000192	CcSEcCtD
Sorafenib—Asthenia—Gabapentin—epilepsy syndrome	2.25e-05	0.000191	CcSEcCtD
Sorafenib—Nausea—Valproic Acid—epilepsy syndrome	2.25e-05	0.000191	CcSEcCtD
Sorafenib—Pruritus—Gabapentin—epilepsy syndrome	2.22e-05	0.000189	CcSEcCtD
Sorafenib—Vomiting—Pregabalin—epilepsy syndrome	2.18e-05	0.000185	CcSEcCtD
Sorafenib—Gastrointestinal pain—Topiramate—epilepsy syndrome	2.16e-05	0.000183	CcSEcCtD
Sorafenib—Rash—Pregabalin—epilepsy syndrome	2.16e-05	0.000183	CcSEcCtD
Sorafenib—Dermatitis—Pregabalin—epilepsy syndrome	2.16e-05	0.000183	CcSEcCtD
Sorafenib—Diarrhoea—Gabapentin—epilepsy syndrome	2.15e-05	0.000182	CcSEcCtD
Sorafenib—Headache—Pregabalin—epilepsy syndrome	2.15e-05	0.000182	CcSEcCtD
Sorafenib—Urticaria—Topiramate—epilepsy syndrome	2.1e-05	0.000178	CcSEcCtD
Sorafenib—Abdominal pain—Topiramate—epilepsy syndrome	2.09e-05	0.000177	CcSEcCtD
Sorafenib—Body temperature increased—Topiramate—epilepsy syndrome	2.09e-05	0.000177	CcSEcCtD
Sorafenib—Dizziness—Gabapentin—epilepsy syndrome	2.08e-05	0.000176	CcSEcCtD
Sorafenib—Nausea—Pregabalin—epilepsy syndrome	2.04e-05	0.000173	CcSEcCtD
Sorafenib—Vomiting—Gabapentin—epilepsy syndrome	2e-05	0.000169	CcSEcCtD
Sorafenib—Rash—Gabapentin—epilepsy syndrome	1.98e-05	0.000168	CcSEcCtD
Sorafenib—Dermatitis—Gabapentin—epilepsy syndrome	1.98e-05	0.000168	CcSEcCtD
Sorafenib—Headache—Gabapentin—epilepsy syndrome	1.97e-05	0.000167	CcSEcCtD
Sorafenib—Hypersensitivity—Topiramate—epilepsy syndrome	1.95e-05	0.000165	CcSEcCtD
Sorafenib—Asthenia—Topiramate—epilepsy syndrome	1.9e-05	0.000161	CcSEcCtD
Sorafenib—Pruritus—Topiramate—epilepsy syndrome	1.87e-05	0.000159	CcSEcCtD
Sorafenib—Nausea—Gabapentin—epilepsy syndrome	1.87e-05	0.000158	CcSEcCtD
Sorafenib—Diarrhoea—Topiramate—epilepsy syndrome	1.81e-05	0.000153	CcSEcCtD
Sorafenib—Dizziness—Topiramate—epilepsy syndrome	1.75e-05	0.000148	CcSEcCtD
Sorafenib—Vomiting—Topiramate—epilepsy syndrome	1.68e-05	0.000143	CcSEcCtD
Sorafenib—Rash—Topiramate—epilepsy syndrome	1.67e-05	0.000141	CcSEcCtD
Sorafenib—Dermatitis—Topiramate—epilepsy syndrome	1.67e-05	0.000141	CcSEcCtD
Sorafenib—Headache—Topiramate—epilepsy syndrome	1.66e-05	0.00014	CcSEcCtD
Sorafenib—Nausea—Topiramate—epilepsy syndrome	1.57e-05	0.000133	CcSEcCtD
Sorafenib—KDR—Signaling Pathways—VEGFA—epilepsy syndrome	6.57e-07	6.17e-06	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—AKT1—epilepsy syndrome	6.56e-07	6.17e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MTOR—epilepsy syndrome	6.53e-07	6.13e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MTOR—epilepsy syndrome	6.53e-07	6.13e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PLCB1—epilepsy syndrome	6.5e-07	6.11e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ABCG2—epilepsy syndrome	6.48e-07	6.09e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—TH—epilepsy syndrome	6.48e-07	6.09e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—JUN—epilepsy syndrome	6.47e-07	6.08e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCL2—epilepsy syndrome	6.45e-07	6.06e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—POMC—epilepsy syndrome	6.43e-07	6.04e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—SLC2A1—epilepsy syndrome	6.42e-07	6.03e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—JUN—epilepsy syndrome	6.41e-07	6.02e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GPX1—epilepsy syndrome	6.39e-07	6e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	6.38e-07	5.99e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—POMC—epilepsy syndrome	6.37e-07	5.99e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—SRC—epilepsy syndrome	6.37e-07	5.99e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ADRA2A—epilepsy syndrome	6.37e-07	5.98e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PLCB1—epilepsy syndrome	6.35e-07	5.96e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—BCHE—epilepsy syndrome	6.34e-07	5.96e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TSC2—epilepsy syndrome	6.33e-07	5.95e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—TH—epilepsy syndrome	6.32e-07	5.94e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AGT—epilepsy syndrome	6.32e-07	5.94e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—RELA—epilepsy syndrome	6.32e-07	5.94e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP2C19—epilepsy syndrome	6.32e-07	5.93e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ADRA2A—epilepsy syndrome	6.31e-07	5.93e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—RELA—epilepsy syndrome	6.3e-07	5.92e-06	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—AKT1—epilepsy syndrome	6.3e-07	5.92e-06	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—AKT1—epilepsy syndrome	6.3e-07	5.92e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MMP9—epilepsy syndrome	6.29e-07	5.91e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—BCHE—epilepsy syndrome	6.28e-07	5.9e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP11A1—epilepsy syndrome	6.28e-07	5.9e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GPX1—epilepsy syndrome	6.24e-07	5.86e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MMP9—epilepsy syndrome	6.23e-07	5.86e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	6.23e-07	5.86e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MTOR—epilepsy syndrome	6.2e-07	5.82e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—APOE—epilepsy syndrome	6.19e-07	5.82e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MTOR—epilepsy syndrome	6.18e-07	5.81e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—POMC—epilepsy syndrome	6.16e-07	5.79e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—SRC—epilepsy syndrome	6.15e-07	5.78e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	6.14e-07	5.76e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	6.14e-07	5.76e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—FGF2—epilepsy syndrome	6.12e-07	5.75e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KDR—epilepsy syndrome	6.07e-07	5.7e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—HMOX1—epilepsy syndrome	6.06e-07	5.69e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—SLC2A1—epilepsy syndrome	6.05e-07	5.68e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PTGS2—epilepsy syndrome	6.04e-07	5.68e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PTGS2—epilepsy syndrome	6.04e-07	5.68e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCL2—epilepsy syndrome	6.03e-07	5.67e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CASP3—epilepsy syndrome	6e-07	5.64e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CASP3—epilepsy syndrome	6e-07	5.64e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—SLC2A1—epilepsy syndrome	6e-07	5.63e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PLCB1—epilepsy syndrome	5.98e-07	5.62e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CAT—epilepsy syndrome	5.98e-07	5.62e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—TH—epilepsy syndrome	5.96e-07	5.6e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PLCB1—epilepsy syndrome	5.93e-07	5.57e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—TH—epilepsy syndrome	5.91e-07	5.55e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—ALB—epilepsy syndrome	5.86e-07	5.51e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PRKCB—epilepsy syndrome	5.84e-07	5.49e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—FGF2—epilepsy syndrome	5.83e-07	5.48e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—JUN—epilepsy syndrome	5.83e-07	5.48e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—JUN—epilepsy syndrome	5.83e-07	5.48e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6ST—epilepsy syndrome	5.82e-07	5.47e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	5.82e-07	5.47e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ABCB1—epilepsy syndrome	5.82e-07	5.46e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—ALB—epilepsy syndrome	5.81e-07	5.46e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—SRC—epilepsy syndrome	5.8e-07	5.45e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—SRC—epilepsy syndrome	5.75e-07	5.4e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CASP3—epilepsy syndrome	5.7e-07	5.35e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CASP3—epilepsy syndrome	5.68e-07	5.34e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	5.68e-07	5.34e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—SRC—epilepsy syndrome	5.68e-07	5.34e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—RELA—epilepsy syndrome	5.68e-07	5.33e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MMP9—epilepsy syndrome	5.67e-07	5.33e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MMP9—epilepsy syndrome	5.67e-07	5.33e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP2D6—epilepsy syndrome	5.66e-07	5.32e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—VEGFA—epilepsy syndrome	5.65e-07	5.31e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AGT—epilepsy syndrome	5.6e-07	5.26e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—VEGFA—epilepsy syndrome	5.6e-07	5.26e-06	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—AKT1—epilepsy syndrome	5.58e-07	5.24e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MTOR—epilepsy syndrome	5.57e-07	5.23e-06	CbGpPWpGaD
Sorafenib—MAPK11—Gene Expression—AKT1—epilepsy syndrome	5.55e-07	5.21e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—JUN—epilepsy syndrome	5.54e-07	5.2e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—JUN—epilepsy syndrome	5.52e-07	5.19e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—APOE—epilepsy syndrome	5.49e-07	5.16e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AGT—epilepsy syndrome	5.47e-07	5.14e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—FGF2—epilepsy syndrome	5.45e-07	5.12e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—RELA—epilepsy syndrome	5.41e-07	5.09e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—HMOX1—epilepsy syndrome	5.41e-07	5.08e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GPX1—epilepsy syndrome	5.41e-07	5.08e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ADRA2A—epilepsy syndrome	5.39e-07	5.07e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MMP9—epilepsy syndrome	5.39e-07	5.06e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MMP9—epilepsy syndrome	5.37e-07	5.05e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—BCHE—epilepsy syndrome	5.37e-07	5.05e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—APOE—epilepsy syndrome	5.36e-07	5.04e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CAT—epilepsy syndrome	5.34e-07	5.01e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—POMC—epilepsy syndrome	5.32e-07	5e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MTOR—epilepsy syndrome	5.31e-07	4.99e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—HMOX1—epilepsy syndrome	5.28e-07	4.96e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—SRC—epilepsy syndrome	5.23e-07	4.92e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—SRC—epilepsy syndrome	5.23e-07	4.92e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CAT—epilepsy syndrome	5.21e-07	4.89e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCL2—epilepsy syndrome	5.21e-07	4.89e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ABCB1—epilepsy syndrome	5.19e-07	4.88e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTGS2—epilepsy syndrome	5.13e-07	4.82e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—SLC2A1—epilepsy syndrome	5.12e-07	4.81e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CASP3—epilepsy syndrome	5.12e-07	4.81e-06	CbGpPWpGaD
Sorafenib—BRAF—Disease—AKT1—epilepsy syndrome	5.1e-07	4.79e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—VEGFA—epilepsy syndrome	5.1e-07	4.79e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—VEGFA—epilepsy syndrome	5.1e-07	4.79e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTGS2—epilepsy syndrome	5.08e-07	4.78e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PLCB1—epilepsy syndrome	5.07e-07	4.76e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—RELA—epilepsy syndrome	5.06e-07	4.75e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—TH—epilepsy syndrome	5.05e-07	4.74e-06	CbGpPWpGaD
Sorafenib—KIT—Immune System—AKT1—epilepsy syndrome	5.03e-07	4.72e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—AKT1—epilepsy syndrome	5.03e-07	4.72e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	5e-07	4.7e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—HMOX1—epilepsy syndrome	4.97e-07	4.67e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—JUN—epilepsy syndrome	4.97e-07	4.67e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	4.97e-07	4.67e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—SRC—epilepsy syndrome	4.96e-07	4.66e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MTOR—epilepsy syndrome	4.96e-07	4.66e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—SRC—epilepsy syndrome	4.95e-07	4.65e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—HMOX1—epilepsy syndrome	4.93e-07	4.63e-06	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—AKT1—epilepsy syndrome	4.93e-07	4.63e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CAT—epilepsy syndrome	4.91e-07	4.61e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CASP3—epilepsy syndrome	4.88e-07	4.59e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	4.87e-07	4.58e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CAT—epilepsy syndrome	4.87e-07	4.57e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	4.84e-07	4.55e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MMP9—epilepsy syndrome	4.84e-07	4.55e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—VEGFA—epilepsy syndrome	4.84e-07	4.54e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GPX1—epilepsy syndrome	4.83e-07	4.53e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—VEGFA—epilepsy syndrome	4.82e-07	4.53e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ABCB1—epilepsy syndrome	4.77e-07	4.49e-06	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—AKT1—epilepsy syndrome	4.77e-07	4.48e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—AKT1—epilepsy syndrome	4.76e-07	4.47e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—JUN—epilepsy syndrome	4.74e-07	4.46e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AGT—epilepsy syndrome	4.74e-07	4.45e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ABCB1—epilepsy syndrome	4.73e-07	4.45e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—POMC—epilepsy syndrome	4.71e-07	4.43e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GPX1—epilepsy syndrome	4.71e-07	4.43e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FGF2—epilepsy syndrome	4.71e-07	4.42e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—APOE—epilepsy syndrome	4.65e-07	4.36e-06	CbGpPWpGaD
Sorafenib—KIT—Disease—AKT1—epilepsy syndrome	4.64e-07	4.36e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP9—epilepsy syndrome	4.61e-07	4.34e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—POMC—epilepsy syndrome	4.61e-07	4.33e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CASP3—epilepsy syndrome	4.56e-07	4.29e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—AKT1—epilepsy syndrome	4.48e-07	4.21e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—SRC—epilepsy syndrome	4.46e-07	4.19e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GPX1—epilepsy syndrome	4.44e-07	4.17e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—JUN—epilepsy syndrome	4.43e-07	4.17e-06	CbGpPWpGaD
Sorafenib—FGFR1—Disease—AKT1—epilepsy syndrome	4.41e-07	4.14e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GPX1—epilepsy syndrome	4.4e-07	4.13e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—AKT1—epilepsy syndrome	4.39e-07	4.13e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	4.37e-07	4.11e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—RELA—epilepsy syndrome	4.37e-07	4.1e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—epilepsy syndrome	4.35e-07	4.08e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—epilepsy syndrome	4.31e-07	4.05e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AKT1—epilepsy syndrome	4.3e-07	4.04e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ALB—epilepsy syndrome	4.3e-07	4.04e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—AKT1—epilepsy syndrome	4.29e-07	4.03e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MTOR—epilepsy syndrome	4.28e-07	4.02e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—SRC—epilepsy syndrome	4.25e-07	4e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AGT—epilepsy syndrome	4.23e-07	3.98e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—HMOX1—epilepsy syndrome	4.21e-07	3.96e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ALB—epilepsy syndrome	4.2e-07	3.95e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AKT1—epilepsy syndrome	4.19e-07	3.94e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AKT1—epilepsy syndrome	4.18e-07	3.93e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	4.16e-07	3.91e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CAT—epilepsy syndrome	4.16e-07	3.91e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—APOE—epilepsy syndrome	4.15e-07	3.9e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—BCHE—epilepsy syndrome	4.14e-07	3.89e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—epilepsy syndrome	4.14e-07	3.89e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AGT—epilepsy syndrome	4.13e-07	3.88e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—APOE—epilepsy syndrome	4.05e-07	3.8e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ABCB1—epilepsy syndrome	4.04e-07	3.8e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—POMC—epilepsy syndrome	3.99e-07	3.75e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—SRC—epilepsy syndrome	3.98e-07	3.74e-06	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AKT1—epilepsy syndrome	3.98e-07	3.74e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—AKT1—epilepsy syndrome	3.96e-07	3.72e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	3.95e-07	3.71e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CASP3—epilepsy syndrome	3.94e-07	3.7e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	3.91e-07	3.67e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TH—epilepsy syndrome	3.9e-07	3.66e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AGT—epilepsy syndrome	3.89e-07	3.66e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—epilepsy syndrome	3.87e-07	3.64e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AGT—epilepsy syndrome	3.86e-07	3.63e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—JUN—epilepsy syndrome	3.83e-07	3.6e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—AKT1—epilepsy syndrome	3.82e-07	3.59e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOE—epilepsy syndrome	3.81e-07	3.58e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOE—epilepsy syndrome	3.78e-07	3.55e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GPX1—epilepsy syndrome	3.76e-07	3.53e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—epilepsy syndrome	3.76e-07	3.53e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—epilepsy syndrome	3.72e-07	3.5e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—epilepsy syndrome	3.67e-07	3.45e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ALB—epilepsy syndrome	3.64e-07	3.42e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AKT1—epilepsy syndrome	3.61e-07	3.39e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AKT1—epilepsy syndrome	3.61e-07	3.39e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AKT1—epilepsy syndrome	3.57e-07	3.36e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—POMC—epilepsy syndrome	3.56e-07	3.35e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—AKT1—epilepsy syndrome	3.53e-07	3.32e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—POMC—epilepsy syndrome	3.48e-07	3.27e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SRC—epilepsy syndrome	3.43e-07	3.23e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—epilepsy syndrome	3.34e-07	3.14e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AGT—epilepsy syndrome	3.3e-07	3.1e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—POMC—epilepsy syndrome	3.28e-07	3.08e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	3.25e-07	3.06e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AKT1—epilepsy syndrome	3.25e-07	3.05e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AKT1—epilepsy syndrome	3.25e-07	3.05e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—POMC—epilepsy syndrome	3.25e-07	3.05e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ALB—epilepsy syndrome	3.25e-07	3.05e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOE—epilepsy syndrome	3.23e-07	3.04e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CAT—epilepsy syndrome	3.21e-07	3.02e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—epilepsy syndrome	3.18e-07	2.99e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ALB—epilepsy syndrome	3.17e-07	2.98e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	3.12e-07	2.93e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AKT1—epilepsy syndrome	3.09e-07	2.9e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AKT1—epilepsy syndrome	3.08e-07	2.89e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AKT1—epilepsy syndrome	3.04e-07	2.85e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AKT1—epilepsy syndrome	3.04e-07	2.85e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ALB—epilepsy syndrome	2.99e-07	2.81e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ALB—epilepsy syndrome	2.96e-07	2.78e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GPX1—epilepsy syndrome	2.9e-07	2.73e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—epilepsy syndrome	2.84e-07	2.67e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—POMC—epilepsy syndrome	2.78e-07	2.61e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—epilepsy syndrome	2.77e-07	2.61e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AKT1—epilepsy syndrome	2.77e-07	2.6e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AKT1—epilepsy syndrome	2.64e-07	2.48e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—epilepsy syndrome	2.61e-07	2.46e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—epilepsy syndrome	2.59e-07	2.43e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AKT1—epilepsy syndrome	2.58e-07	2.42e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AKT1—epilepsy syndrome	2.56e-07	2.4e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AGT—epilepsy syndrome	2.54e-07	2.39e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALB—epilepsy syndrome	2.53e-07	2.38e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOE—epilepsy syndrome	2.49e-07	2.34e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AKT1—epilepsy syndrome	2.47e-07	2.32e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—epilepsy syndrome	2.21e-07	2.08e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—POMC—epilepsy syndrome	2.14e-07	2.01e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AKT1—epilepsy syndrome	2.13e-07	2e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALB—epilepsy syndrome	1.95e-07	1.83e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AKT1—epilepsy syndrome	1.89e-07	1.78e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AKT1—epilepsy syndrome	1.85e-07	1.74e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	1.71e-07	1.61e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AKT1—epilepsy syndrome	1.6e-07	1.5e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AKT1—epilepsy syndrome	1.43e-07	1.34e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AKT1—epilepsy syndrome	1.39e-07	1.31e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AKT1—epilepsy syndrome	1.31e-07	1.23e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AKT1—epilepsy syndrome	1.3e-07	1.22e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AKT1—epilepsy syndrome	1.11e-07	1.05e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKT1—epilepsy syndrome	8.59e-08	8.07e-07	CbGpPWpGaD
